When was Alder Biopharmaceuticals founded?

Alder Biopharmaceuticals was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Where is Alder Biopharmaceuticals located?

Alder Biopharmaceuticals is headquartered in Bothell, United States.

How many employees does Alder Biopharmaceuticals have?

As of Mar 01, 2026, the latest employee count at Alder Biopharmaceuticals is 50 - 199.

Is Alder Biopharmaceuticals a funded company?

Alder Biopharmaceuticals is a funded company, having raised a total of $105M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 09, 2005.

When was the latest funding round of Alder Biopharmaceuticals?

Alder Biopharmaceuticals' latest funding was a $***** Post IPO round on Feb 26, 2018, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $7.48B in funding in 2026 to date.

Where does Alder Biopharmaceuticals rank among its competitors?

Alder Biopharmaceuticals ranks 416th amongst 3456 active competitors, of which 1132 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Alder Biopharmaceuticals?

Alder Biopharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Alder Biopharmaceuticals - 2026 Company Profile, Funding & Competitors

Alder Biopharmaceuticals is an acquired company based in Bothell (United States), founded in 2004. It operates as a Humanized monoclonal antibody based therapeutics for migraine and inflammatory diseases. Alder Biopharmaceuticals has raised $105M in funding from investors like Sevin Rosen, TPG and Ventures West. The company has 3456 active competitors, including 1132 funded and 794 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Key Metrics

Founded Year

2004

Location

Bothell, United States

Stage

Acquired

Total Funding

$105M in 5 rounds

Latest Funding Round

Post IPO, Feb 26, 2018, $*****

Investors

Sevin Rosen & 10 more

Ranked

416^th among 3456 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

BeiGene & 673 more

Exit Details

Acquired by Lundbeck (Sep 16, 2019)

View Alder Biopharmaceuticals' full profile

Alder Biopharmaceuticals got acquired by Lundbeck on Sep 16, 2019 at an acquisition amount of $*****.

Click here to take a look at Alder Biopharmaceuticals's acquisition in detail

Alder Biopharmaceuticals has raised a total funding of $105M over 5 rounds. Its first funding round was on Aug 09, 2005. Alder Biopharmaceuticals has 11 institutional investors.

Here is the list of recent funding rounds of Alder Biopharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 26, 2018	3059753	Post IPO	5217644	9392104	7160563	4739552
Apr 19, 2012	3156007	Series D	9147148	4837889	5984240	Ventures West & 5 more
Jan 11, 2008	2634890	Series C	5819692	1134861	Delphi Ventures & 1 more	H.I.G. Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Alder Biopharmaceuticals's funding rounds and investors

Alder Biopharmaceuticals' employee count trend

Alder Biopharmaceuticals has 50 - 199 employees as of Mar 26. Here is Alder Biopharmaceuticals's employee count trend over the years:

Employee count trend for Alder Biopharmaceuticals

Uncover Alder Biopharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alder Biopharmaceuticals include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Alder Biopharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
416th	Alder Biopharmaceuticals 2004, Bothell (United States), Acquired	Humanized monoclonal antibody based therapeutics for migraine and inflammatory diseases	$105M	Foresite Capital, New Leaf Venture Partners ... & 9 others	54/100